KeyNeurotek Gets €8.2M for Overactive Bladder Program
BioWorld Today Correspondent
KeyNeurotek Pharmaceuticals AG completed a second closing of an internal Series C round, raising the total value of the deal to €8.2 million (US$10.9 million).
Although no new investors bought into the company, all its "main existing investors" did participate, Magdeburg, Germany-based KeyNeurotek said.
Those include Munich-based Deutsche Venture Capital, IBG Beteiligungsgesellschaft, of Magdeburg, and Bonn-based KfW.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter